Pemafate0.1 mg

Pemafate is indicated as an adjunct to diet and other non-pharmacological measures for the treatment of hypertriglyceridemia (elevated fasting triglyceride levels) in adults, including patients with mixed dyslipidemia, when triglyceride-lowering therapy is required.

• Established/guideline-supported use: Severe or moderate-to-severe hypertriglyceridemia not adequately controlled by diet, exercise, and weight management alone.
• Adjunct use: May be used in combination with a statin in patients with mixed dyslipidemia (elevated LDL-C and triglycerides) who require additional triglyceride and non-HDL-C lowering, under close monitoring.
• Evidence note: Pemafate lowers triglycerides and raises HDL-cholesterol; however, large outcome trials have not demonstrated a reduction in cardiovascular events when Pemafate is added to statin therapy in patients with type 2 diabetes and mixed dyslipidemia. It should therefore not be used as a substitute for statin therapy where statins are indicated for cardiovascular risk reduction.

Each tablet contains Pemafibrate as the active pharmaceutical ingredient, along with standard pharmaceutical excipients such as lactose, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, and a film-coating system. Strength per tablet follows the locally registered formulation (commonly 0.1 mg per tablet in markets where it is available); refer to the specific product label for exact strength and excipient details.

Pemafate is a selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha), a novel class of lipid-modifying agent developed to activate PPAR-alpha with greater selectivity and potency than older fibrates such as fenofibrate and gemfibrozil.

By selectively engaging PPAR-alpha, Pemafate produces potent reductions in serum triglycerides and increases in HDL-cholesterol, while aiming to minimize the off-target effects (such as hepatic and renal function changes) seen with less selective fibrates. Pemafate is administered orally and is used specifically for triglyceride-lowering therapy rather than as a first-line agent for LDL-cholesterol reduction.

Pemafate belongs to the Selective PPAR-alpha Modulator (SPPARM-alpha) class, a distinct subclass within lipid-regulating agents that is pharmacologically related to, but structurally and functionally distinguished from, the traditional fibrate class of triglyceride-lowering drugs.

Mechanism of Action

Pemafibrate selectively activates the peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear transcription factor that regulates genes involved in lipid metabolism. Activation of PPAR-alpha by Pemafibrate leads to:

• Increased expression and activity of lipoprotein lipase (LPL), enhancing hydrolysis and clearance of triglyceride-rich lipoproteins.
• Decreased hepatic expression of apolipoprotein C-III (apoC-III), an inhibitor of LPL, further promoting triglyceride clearance.
• Increased expression of apolipoprotein A-V, which facilitates triglyceride-rich lipoprotein catabolism.
• Modest increases in HDL-cholesterol via enhanced apolipoprotein A-I and A-II production.

Pharmacokinetics

Pemafibrate is well absorbed after oral administration, is highly bound to plasma proteins, and is extensively metabolized in the liver, primarily via CYP2C8 and CYP3A4 pathways with subsequent glucuronidation, followed by predominant biliary/fecal excretion. Its selectivity for PPAR-alpha over PPAR-gamma and PPAR-delta is substantially higher than that of older fibrates, which is proposed to underlie its favorable tolerability profile at low milligram doses.

Pemafate is administered orally, typically twice daily after meals, with a full glass of water. Tablets should be swallowed whole and not crushed or chewed unless otherwise directed. Consistent timing with meals helps maintain steady drug levels and supports adherence to concurrent dietary therapy.

The following clinically significant interactions have been established for Pemafate:

• Cyclosporine: Concomitant use is contraindicated. Cyclosporine markedly increases Pemafate plasma concentrations (via inhibition of hepatic uptake transporters), substantially raising the risk of Pemafate-related toxicity.
• Strong CYP2C8/OATP inhibitors: Co-administration with strong inhibitors of CYP2C8 or organic anion-transporting polypeptides can significantly increase Pemafate exposure; such combinations should be avoided or require dose adjustment and close monitoring.
• Rifampicin and other strong enzyme inducers: May reduce Pemafate plasma concentrations and diminish its lipid-lowering effect.
• HMG-CoA reductase inhibitors (statins): Concurrent use increases the risk of myopathy and rhabdomyolysis; although this risk is considered lower with Pemafate than with older fibrates such as gemfibrozil, patients on combination therapy should be monitored for muscle pain, tenderness, or weakness.
• Oral anticoagulants (e.g., warfarin): Pemafate may potentiate anticoagulant effect; more frequent INR monitoring and dose adjustment of the anticoagulant may be required.
• Other fibrates: Concurrent use with other fibric acid derivatives is generally not recommended due to additive toxicity risk without added benefit.

Adverse effects reported with Pemafate include:

• Common: Elevated liver enzymes (AST/ALT), increased serum creatinine (usually mild and reversible), diarrhea, nausea, abdominal discomfort, and mild increases in creatine kinase.
• Less common: Cholelithiasis (gallstones) with long-term use, headache, back pain, and mild hematologic changes.
• Rare but serious: Myopathy and, very rarely, rhabdomyolysis (risk increased with concomitant statin use — see Interactions); hepatic dysfunction; hypersensitivity reactions including rash.

Patients should report unexplained muscle pain, weakness, dark urine, yellowing of skin/eyes, or persistent abdominal pain to their physician promptly.

Pregnancy: The safety of Pemafate in human pregnancy has not been established. Pemafate should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Reproductive toxicity has been observed in animal studies at doses relevant to clinical use.

Lactation: It is not known whether Pemafate is excreted in human breast milk. Because many lipid-modifying drugs distribute into milk and lipid alteration in a nursing infant is a theoretical concern, a decision should be made whether to discontinue nursing or discontinue Pemafate, taking into account the importance of the drug to the mother; consult a physician.

• Hepatic monitoring: Liver function tests should be performed periodically during Pemafate therapy; discontinue if marked or persistent transaminase elevation occurs.
• Myopathy/rhabdomyolysis: Use caution when combining Pemafate with statins or in patients with risk factors for myopathy (renal impairment, hypothyroidism, advanced age); advise patients to report muscle symptoms promptly.
• Gallstones: Long-term use of Pemafate, like other fibrates, may increase the risk of cholelithiasis; evaluate patients who develop symptoms suggestive of gallbladder disease.
• Renal function: Mild, generally reversible increases in serum creatinine may occur; monitor renal function periodically, particularly in patients with pre-existing renal impairment.
• Cardiovascular outcomes: Pemafate has not been shown to reduce cardiovascular events in large outcome trials when added to statin therapy; it should not be used as a substitute for guideline-directed statin therapy for cardiovascular risk reduction.
• Not an antibiotic: Pemafate is a lipid-modifying agent and has no antimicrobial activity.

There is limited clinical experience with Pemafate overdose. In the event of suspected overdose, seek immediate medical attention or contact a poison control center. Management should be supportive and symptomatic, with monitoring of liver function, renal function, and creatine kinase; there is no specific antidote for Pemafate. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Use with caution; start at the lower end of the dosing range and monitor renal and hepatic function, as elderly patients may have reduced organ reserve and increased susceptibility to adverse effects.
• Renal impairment: Contraindicated in severe renal impairment/dialysis; use with caution and monitoring in mild-to-moderate impairment (see Contraindications and Dosage).
• Hepatic impairment: Contraindicated in severe hepatic impairment/biliary cirrhosis; use with caution and monitoring in mild-to-moderate impairment.
• Pediatric patients: Safety and efficacy not established; not recommended.
• Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of Pemafate therapy is individualized by the prescribing physician based on triglyceride response, tolerability, and ongoing cardiovascular risk assessment. Treatment is typically long-term/chronic for management of hypertriglyceridemia, with periodic reassessment of lipid profile, liver function, and renal function (generally every few months, or as directed by the physician) to confirm continued benefit and safety.

Pemafibrate is classified as a Selective PPAR-alpha Modulator (SPPARM-alpha), a lipid-modifying agent within the broader category of triglyceride-lowering drugs, pharmacologically related to but distinct from conventional fibrates.

Pemafibrate works by selectively and potently activating peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor that governs transcription of genes controlling lipid and lipoprotein metabolism. This activation increases lipoprotein lipase activity and apolipoprotein A-V expression while decreasing apolipoprotein C-III, resulting in enhanced clearance of triglyceride-rich lipoproteins and a net reduction in serum triglycerides with an increase in HDL-cholesterol.

The safety and efficacy of Pemafate have not been established in pediatric patients (under 18 years of age). Pemafate is therefore not recommended for use in children or adolescents outside of a clinical trial setting.